EQS-Ad-hoc: Semperit AG Holding / Key word(s): Dividend Ad-hoc information Semperit Executive Board proposes basic dividend of EUR 1.50 per share plus a conditional additional dividend of EUR 2.00 to EUR 3.50 per share for 2022 Vienna, Austria, 1 March 2023 – The Executive Board of Semperit AG Holding has decided to propose to the Annual General Meeting a basic dividend of EUR 1.50 per share as well as a conditional additional dividend of EUR 2.00 to EUR 3.50 per share for the 2022 financial year. This results in a total dividend proposal of a maximum of EUR 5.00 per share for the 2022 financial year (previous year: EUR 1.50 per share). The basic dividend will be paid out on 3 May 2023. The entitlement to the additional dividend depends on the sale of the medical business (Sempermed; production of examination gloves including sales organisation first) by 30 September 2023. The closing of the sale of the medical business is, in particular, still subject to the approval of the foreign direct investment control and competition authorities. The exact amount of the additional dividend proposal depends on the economic outlook and on organic and inorganic growth projects becoming more substantiated. The Executive Board will announce a more concrete additional dividend proposal in due time before the Annual General Meeting of Semperit AG Holding on 25 April 2023. This one-time deviation from the dividend policy of Semperit AG Holding should be seen in light of the successful separation from the medical business.
For questions, please contact:
www.linkedin.com/company/semperit-ag
01-March-2023 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
Language: | English |
Company: | Semperit AG Holding |
Am Belvedere 10 | |
1100 Wien | |
Austria | |
Phone: | +43 1 79 777-310 |
Fax: | +43 1 79 777-602 |
E-mail: | judit.helenyi@semperitgroup.com |
Internet: | www.semperitgroup.com |
ISIN: | AT0000785555 |
Listed: | Vienna Stock Exchange (Official Market) |
EQS News ID: | 1572419 |
End of Announcement | EQS News Service |
|
1572419 01-March-2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.